An Adverse Reaction to Buprenorphine/Naloxone Induction in Prison: A Case Report

March 2, 2016

Buprenorphine is an effective treatment for opiate dependence. Prisoners with histories of opiate dependence who are inducted on buprenorphine prior to release are at decreased risk of post-release relapse and overdose, yet many clinicians are unaware of the risks related to buprenorphine induction for non-opiate tolerant patients, especially those on other psychotropic medications. The authors […]

Read the full article →

MonoSol Rx Announces Listing of Patent in FDA Orange Book for Suboxone(R) Sublingual Films

March 2, 2016

WARREN, N.J., Nov. 30, 2011 (GLOBE NEWSWIRE) — MonoSol Rx, LLC (“MonoSol Rx”), the developer of PharmFilm(r) drug delivery technology and a drug delivery company specializing in film pharmaceutical products, announced that the U.S. Food and Drug Administration (FDA) has listed MonoSol Rx’s U.S. Patent No. 8,017,150 in the Orange Book for the Suboxone(r) (buprenorphine […]

Read the full article →

Adjunctive Counseling During Brief and Extended Buprenorphine-Naloxone Treatment for Prescription Opioid Dependence: A 2-Phase Randomized Controlled Trial [Original Article]

March 2, 2016

Conclusions  Prescription opioid–dependent patients are most likely to reduce opioid use during buprenorphine-naloxone treatment; if tapered off buprenorphine-naloxone, even after 12 weeks of treatment, the likelihood of an unsuccessful outcome is high, even in patients receiving counseling in addition to SMM. Trial Registration  clinicaltrials.gov Identifier: NCT00316277 (Source: Archives of General Psychiatry)

Read the full article →

Diversion and abuse of buprenorphine: Findings from national surveys of treatment patients and physicians

March 2, 2016

Conclusions: The increases in diversion and abuse measures indicate the need to take active attempts to curb diversion and abuse as well as continuous monitoring and surveillance of all buprenorphine products. However, these increases parallel the increased number of tablets sold. Finding a balance of risk/benefit (i.e. diversion and abuse versus expanded treatment) remains a […]

Read the full article →

Update on the clinical use of buprenorphine: In opioid-related disorders.

March 2, 2016

Conclusion Buprenorphine is a safe and effective agent for detoxification from opioids. It can be used as a first-line agent in maintenance programs, owing to its lower abuse potential relative to other opioids. Its effectiveness in primary care settings makes it a useful therapeutic tool for family physicians. PMID: 22267618 [PubMed – in process] (Source: […]

Read the full article →

The 2nd Annual Alexander Awards: Best Tox Reading of 2011

March 2, 2016

Alexander Gettler Taking inspiration from New York Times columnist David Brooks and his annual Sidney Awards for the best magazine essays of the preceding year, TPR is proud to present its Alexander Awards for the best toxicology writing on the web in 2011. The awards are named after Alexander Gettler, who was New York City’s chief […]

Read the full article →

Cost-Effectiveness of Long-Term Outpatient Buprenorphine-Naloxone Treatment for Opioid Dependence in Primary Care

March 2, 2016

CONCLUSIONS  Office-based bup/nx for clinically stable patients may be a cost-effective alternative to no treatment at a threshold of $100,000/QALY depending on assumptions about quality-of-life weights. Additional research about quality-of-life benefits and broader health system and societal cost savings of bup/nx therapy is needed. Content Type Journal ArticleCategory Original ResearchPages 1-8DOI 10.1007/s11606-011-1962-8Authors Bruce R. Schackman, Department […]

Read the full article →

A Comparison of Suboxone and Clonidine Treatment Outcomes in Opiate Detoxification

March 2, 2016

Conclusions: Suboxone treatment decreased premature termination of opioid detoxification completion when compared with clonidine. (Source: Archives of Psychiatric Nursing)

Read the full article →

SUBOXONE (Buprenorphine Hydrochloride, Naloxone Hydrochloride) Tablet [Reckitt Benckiser Pharmaceuticals Inc.]

March 2, 2016

Updated Date: Jan 18, 2012 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Read the full article →

The history of the development of buprenorphine as an addiction therapeutic

March 2, 2016

This paper traces the early 21st century success of the agonist–antagonist buprenorphine and the combination drug buprenorphine with naloxone within the broader quest to develop addiction therapeutics that began in the 1920s as the search for a nonaddictive analgesic. Drawing on archival research, document analysis, and interviews with contemporary actors, this paper situates the social […]

Read the full article →

← Previous Entries

Next Entries →